Frontier Biotechnologies Dirección

Dirección controles de criterios 3/4

El CEO de Frontier Biotechnologies es C. J. Wang, nombrado en Jan 2013, tiene una permanencia de 11.83 años. posee directamente un 5.62% de las acciones de la empresa, con un valor de CN¥156.47M. La antigüedad media del equipo directivo y de la junta directiva es de 10.3 años y 6.5 años, respectivamente.

Información clave

C. J. Wang

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	11.8yrs
Participación del CEO	5.6%
Permanencia media de la dirección	10.3yrs
Promedio de permanencia en la Junta Directiva	6.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

C. J. Wang (66 yo)

11.8yrs

Permanencia

CN¥2,228,000

Compensación

Dr. Changjin Wang, also known as C. J., Ph D., serves as Chief Executive Officer and Director at Frontier Biotechnologies Inc. since January 2013. Dr. Wang served as Vice President of Business Development...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Qi Shao	Senior VP & CFO	8.8yrs	CN¥1.37m	sin datos
Rongjian Lu	CTO & Director	11.8yrs	CN¥1.88m	5.8% CN¥ 161.6m
Yuting Zhu	Supervisor & Deputy GM Administrative Director	no data	CN¥593.80k	sin datos
Hangzhou Lv	Senior Vice President of Marketing & Sales	no data	CN¥1.22m	sin datos
Qianya Gao	Deputy GM & Secretary of the Board of Directors	3.9yrs	CN¥962.00k	sin datos
Dong Xie	Founder	11.8yrs	CN¥2.26m	3.72% CN¥ 103.4m
Changjin Wang	MD, CEO & Director	11.8yrs	CN¥2.23m	5.62% CN¥ 156.5m
Xiao Zheng	Chief Operating Officer	3.7yrs	CN¥3.47m	sin datos
Michael Hu	C.M.O.	no data	sin datos	sin datos

10.3yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 688221 es experimentado (10.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rongjian Lu	CTO & Director	11.8yrs	CN¥1.88m	5.8% CN¥ 161.6m
Yuting Zhu	Supervisor & Deputy GM Administrative Director	5.8yrs	CN¥593.80k	sin datos
Dong Xie	Founder	11.8yrs	CN¥2.26m	3.72% CN¥ 103.4m
Changjin Wang	MD, CEO & Director	11.8yrs	CN¥2.23m	5.62% CN¥ 156.5m
Chi Kit Ng	Independent Director	5.8yrs	CN¥150.00k	sin datos
Yuantao Cao	Supervisor	6.5yrs	sin datos	sin datos
Guangji Wang	Independent Director	2.5yrs	CN¥130.20k	sin datos
Kai Chen	Independent Director	5.8yrs	CN¥90.70k	sin datos
Zhi Zhong Jiang	Chairman of the Supervisory Board & Purchasing Director	8.8yrs	CN¥380.60k	sin datos

6.5yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de 688221 se considera experimentada (6.5 años de antigüedad promedio).

Frontier Biotechnologies Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.19 loss in 3Q 2023)

Frontier Biotechnologies Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.26 loss in 2Q 2023)

Frontier Biotechnologies Inc. to Report First Half, 2024 Results on Aug 31, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Frontier Biotechnologies Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.29 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.18 loss in 2Q 2022)

Frontier Biotechnologies Inc. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.16 loss in 1Q 2022)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (Mpro) Small Molecule Inhibitor, Laying Foundation for the Treatment of Acute and Long COVID

Frontier Biotechnologies Inc. announced that it expects to receive CNY 270.2 million in funding from Jiezheng Investment Group Co., Ltd, UBS Group AG, Guodu Venture Capital Co., Ltd., Nuode Fund Management Co., Ltd., Guizhou Xiehui Property Development Company Limited

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥22.90

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: CN¥0.23 loss per share (vs CN¥0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.23 loss in 2Q 2020)

Frontier Biotechnologies' First Long-Acting Injectable (Aikening(R)), in A Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Full year 2020 earnings released: CN¥0.80 loss per share (vs CN¥0.73 loss in FY 2019)

New 90-day low: CN¥16.16

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad